HIV, Trauma Exposure
Conditions
Keywords
South Africa, HIV, Mental health, Trauma, Women
Brief summary
In this study, the investigators propose to develop Improving AIDS Care after Trauma (ImpACT), an intervention based on theories of stress and coping and evidence-based treatment for traumatic stress. The intervention will target women in South Africa who have histories of sexual trauma and are newly initiating antiretroviral therapy (ART) in order to reduce avoidant coping and traumatic stress, improve care engagement, and reduce HIV risk behaviors.
Detailed description
HIV-infected women in South Africa report high rates of sexual trauma, which negatively impacts their mental health and potentially influences engagement in HIV care (retention in care and adherence to antiretroviral therapy) and risk behaviors. Addressing the traumatic stress resulting from sexual trauma could improve these HIV-related outcomes, which in turn may prevent HIV transmission through suppression of the virus and reduction in HIV risk behaviors. Intervention research among HIV-infected populations with trauma histories in the U.S. demonstrates that a coping approach, particularly one that reduces the use of avoidant coping strategies, is efficacious in reducing traumatic stress and improving health behaviors. Although South Africa faces dual epidemics of HIV and sexual violence, trauma treatment has not been well-integrated into the HIV care setting. The proposed 3-year study will develop and pilot test an intervention called ImpACT (Improving AIDS Care after Trauma) to reduce avoidant coping, traumatic stress, and risk behaviors, and increase engagement in care. The intervention will take place in a public ART clinic and will target women during the critical period when they initiate ART in order to maximize the impact on engagement in care. Qualitative data collection with staff, providers, and HIV-infected female patients at the study clinic will elicit feedback on the content and delivery of ImpACT and key aspects of the study protocol. ImpACT will then be piloted with 60 women who are new ART enrollees with a history of sexual trauma and elevated traumatic stress. Participants will be randomized to the control condition (standard of care, or SoC: 3 adherence counseling sessions required of all patients initiating ART at the clinic) or the intervention condition (SoC + ImpACT), and will complete assessments at baseline, 3, and 6 months post-randomization, with care engagement data extracted from medical records at the end of the study period. The study has three specific aims: 1) to develop a brief and scalable coping intervention for delivery in the South African HIV care setting for women with sexual trauma histories; 2) to establish the methodological details of an experimental protocol for a robust randomized control trial; and 3) to pilot test the ImpACT intervention with 60 HIV-infected women with histories of sexual trauma who are initiating ART in order to determine feasibility and acceptability in the HIV care setting, and explore the impact on avoidant coping, traumatic stress, engagement in care, and HIV risk behaviors. The goal at the completion of this study is to have a structured intervention curriculum that is culturally relevant for HIV infected women in South Africa, a full experimental protocol that is appropriate for the South African care setting, and data on feasibility, acceptability, and target outcomes. These products can be leveraged to inform an R01 application for rigorous evaluation of the ImpACT intervention. We are confident that this developmental work will significantly enhance the probability of success of a larger randomized control trial.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* HIV infected women who are newly initiating ART at the study clinic * History of sexual trauma * Meets criteria for traumatic stress
Exclusion criteria
* Immediate suicide risk
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PTSD Symptoms | 90 Days, 180 days | Self-report, measured by the PTSD checklist, civilian version (PCL-5). 20-item self-report questionnaire, assessed severity of symptoms that parallel the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria for PTSD. Participants were asked to indicate the extent to which they were bothered by problems experienced in the past month in relation to a traumatic experience of abuse or act of violence (0 = not at all to 4 = extremely). Total severity score (range: 0-80; higher scores indicating higher symptom severity, \>= 33 indicating PTSD) and subscale totals (Avoidance - Cluster C, range: 0-8, higher scores indicating higher avoidance symptom severity; and Hyperarousal - Cluster E, range: 0-24, higher scores indicating higher hyperarousal symptom severity) were examined. |
| HIV Medication Adherence (% Adherent) | 180 days | Assessed through biomarkers of dried blood spots (DBS) testing for presence of antiretroviral therapy (ART) (tenofovir, emtricitabine, and efavirenz) at 6 month assessment, supplemented by viral load (VL; considered adherent if VL \<=40 copies/ml) when DBS unavailable. Outcome dichotomized. |
Countries
South Africa
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Mental Health Treatment The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
Improving AIDS Care after Trauma (ImpACT) | 32 |
| Standard of Care Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment. | 32 |
| Total | 64 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 9 | 4 |
Baseline characteristics
| Characteristic | Standard of Care | Total | Mental Health Treatment |
|---|---|---|---|
| Age, Continuous | 29.0 years STANDARD_DEVIATION 8.4 | 29.1 years STANDARD_DEVIATION 7.5 | 29.2 years STANDARD_DEVIATION 6.6 |
| PTSD Symptoms (PCL-5) PCL - Cluster C Avoidance | 3.03 units on a scale STANDARD_DEVIATION 2.62 | 3.78 units on a scale STANDARD_DEVIATION 2.86 | 4.53 units on a scale STANDARD_DEVIATION 2.93 |
| PTSD Symptoms (PCL-5) PCL - Cluster E Arousal | 8.31 units on a scale STANDARD_DEVIATION 6.34 | 10.59 units on a scale STANDARD_DEVIATION 7.15 | 12.88 units on a scale STANDARD_DEVIATION 7.25 |
| PTSD Symptoms (PCL-5) PCL - total symptom severity score | 30.72 units on a scale STANDARD_DEVIATION 20.27 | 37.00 units on a scale STANDARD_DEVIATION 21.89 | 43.28 units on a scale STANDARD_DEVIATION 21.94 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 32 Participants | 64 Participants | 32 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment South Africa | 32 participants | 64 participants | 32 participants |
| Sex: Female, Male Female | 32 Participants | 64 Participants | 32 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 32 | 0 / 32 |
| other Total, other adverse events | 0 / 32 | 0 / 32 |
| serious Total, serious adverse events | 0 / 32 | 0 / 32 |
Outcome results
HIV Medication Adherence (% Adherent)
Assessed through biomarkers of dried blood spots (DBS) testing for presence of antiretroviral therapy (ART) (tenofovir, emtricitabine, and efavirenz) at 6 month assessment, supplemented by viral load (VL; considered adherent if VL \<=40 copies/ml) when DBS unavailable. Outcome dichotomized.
Time frame: 180 days
Population: Subset of participants newly initiating ART (excluding re-initiators and non-initiators; n=54, 49 with biomarker data)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Mental Health Treatment | HIV Medication Adherence (% Adherent) | 19 Participants |
| Standard of Care | HIV Medication Adherence (% Adherent) | 15 Participants |
PTSD Symptoms
Self-report, measured by the PTSD checklist, civilian version (PCL-5). 20-item self-report questionnaire, assessed severity of symptoms that parallel the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria for PTSD. Participants were asked to indicate the extent to which they were bothered by problems experienced in the past month in relation to a traumatic experience of abuse or act of violence (0 = not at all to 4 = extremely). Total severity score (range: 0-80; higher scores indicating higher symptom severity, \>= 33 indicating PTSD) and subscale totals (Avoidance - Cluster C, range: 0-8, higher scores indicating higher avoidance symptom severity; and Hyperarousal - Cluster E, range: 0-24, higher scores indicating higher hyperarousal symptom severity) were examined.
Time frame: 90 Days, 180 days
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mental Health Treatment | PTSD Symptoms | PCL - total symptom severity (3 mos) | 25.79 score on a scale | Standard Error 5.4 |
| Mental Health Treatment | PTSD Symptoms | PCL - total symptom severity (6 mos) | 28.61 score on a scale | Standard Error 5.04 |
| Mental Health Treatment | PTSD Symptoms | PCL - Cluster C Avoidance (3 mos) | 2.21 score on a scale | Standard Error 0.63 |
| Mental Health Treatment | PTSD Symptoms | PCL - Cluster C Avoidance (6 mos) | 2.96 score on a scale | Standard Error 0.6 |
| Mental Health Treatment | PTSD Symptoms | PCL - Cluster E Hyperarousal (3 mos) | 7.47 score on a scale | Standard Error 1.36 |
| Mental Health Treatment | PTSD Symptoms | PCL - Cluster E Hyperarousal (6 mos) | 7.91 score on a scale | Standard Error 1.54 |
| Standard of Care | PTSD Symptoms | PCL - Cluster E Hyperarousal (3 mos) | 8.00 score on a scale | Standard Error 1.21 |
| Standard of Care | PTSD Symptoms | PCL - total symptom severity (3 mos) | 23.04 score on a scale | Standard Error 3.6 |
| Standard of Care | PTSD Symptoms | PCL - Cluster C Avoidance (6 mos) | 2.71 score on a scale | Standard Error 0.47 |
| Standard of Care | PTSD Symptoms | PCL - total symptom severity (6 mos) | 22.50 score on a scale | Standard Error 3.47 |
| Standard of Care | PTSD Symptoms | PCL - Cluster E Hyperarousal (6 mos) | 6.75 score on a scale | Standard Error 1.1 |
| Standard of Care | PTSD Symptoms | PCL - Cluster C Avoidance (3 mos) | 2.23 score on a scale | Standard Error 0.39 |